Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma.
Twenty-one evaluable patients with metastatic colorectal carcinoma were treated with a combination of continuous-infusion cisplatin (25 mg/m2/day X 3 days) and bolus 5-fluorouracil (400 mg/m2/day X 3 days). Toxicity was minimal. Seven patients (33%) responded. All responses were observed among the 16 previously untreated patients (44%) and lasted a median of 30 weeks. The results indicate the need for phase III trials of this treatment.
Posner
M R
MR
Roger Williams Cancer Center, Providence, RI.
Belliveau
J F
JF
Weitberg
A B
AB
Sabbath
K
K
Wiemann
M C
MC
Cummings
F J
FJ
Calabresi
P
P
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology
D002945:Cisplatin; D005472:Fluorouracil